Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12097975 | 0.88 | BRD9 (0.39) | MAPKAPK2BRD9DGAT1METAP1AAK1 | |
| SCHEMBL15584205 | 0.85 | ATR (0.42) | MAPKAPK2BRD9METAP1MAP4K4AAK1 | |
| SCHEMBL17592970 | 0.85 | AAK1 (0.40) | MAPKAPK2BRD9DGAT1METAP1AAK1 | |
| SCHEMBL14923617 | 0.82 | CYP17A1 (0.43) | MAPKAPK2BRD9DGAT1METAP1AAK1 | |
| SCHEMBL29956827 | 0.81 | ATR (0.39) | MAPKAPK2BRD9DGAT1METAP1MAP4K4 | |
| SCHEMBL29955405 | 0.81 | BRD9 (0.38) | MAPKAPK2BRD9DGAT1METAP1AAK1 | |
| SCHEMBL18624699 | 0.81 | ALDH1A1 (0.40) | BRD9DGAT1AAK1ATR | |
| SCHEMBL10330552 | 0.81 | ATR (0.41) | MAPKAPK2BRD9DGAT1METAP1MAP4K4 | |
| SCHEMBL20320534 | 0.78 | LMNA (0.45) | MAPKAPK2BRD9DGAT1METAP1AAK1 | |
| SCHEMBL2772617 | 0.77 | ATR (0.49) | MAPKAPK2BRD9DGAT1METAP1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MAPKAPK2 60/4885BRD9 420/4885DGAT1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.